Infectious Disease · Medical Literature
WHO Issues Guidelines for Treating Ebola and Marburg Viruses
Abstract
The World Health Organization (WHO) released its first comprehensive guidelines on the clinical management of filovirus disease, which includes all Ebola and Marburg viruses.
Clinical relevance
This JAMA report (published July 2, 2026) highlights the WHO's first-ever comprehensive clinical management guidelines for the entire filovirus family — encompassing Ebola (Zaire, Sudan, Bundibugyo, Taï Forest) and Marburg viruses — filling a critical gap previously addressed only by disease-specific, fragmented guidance. The guidelines arrive amid an active Bundibugyo Ebola outbreak in the Democratic Republic of the Congo and Uganda, directly affecting frontline clinicians managing high-mortality viral hemorrhagic fever in resource-limited settings. With case fatality rates ranging from 25% to 90% and no licensed vaccines or antivirals for Marburg, Sudan, or Bundibugyo virus diseases, these guidelines establish the first globally harmonized evidence-based standard of care for this patient population.
Key findings
1. Scope: The guidelines contain 16 evidence-based recommendations developed using systematic reviews and the GRADE framework, covering all five filovirus species (Ebola, Sudan, Bundibugyo, Taï Forest, Marburg); this is the first document to consolidate clinical guidance across the entire filovirus family. 2. Mortality burden: Case fatality rates across filovirus disease outbreaks range from 25% to 90%, with Marburg virus disease carrying a case fatality ratio of up to 88% — though outcomes can be substantially improved with early, high-quality supportive care (no specific NNT reported in the available abstract). 3. Epidemiologic context: Seventy-two outbreaks of Ebola and Marburg diseases have been reported in Africa since 1967; the current Bundibugyo Ebola outbreak in the DRC recorded at least 837 confirmed cases and 196 deaths in the preceding six months, primarily in Ituri Province. 4. Therapeutic gap: No licensed vaccines or antiviral treatments exist for Marburg virus disease, Bundibugyo virus disease, or Sudan virus disease; the guidelines therefore anchor management in optimized supportive care as the primary survival-improving intervention for these pathogens. 5. Key clinical recommendations include: (a) serial laboratory monitoring to detect and treat hypoglycemia and metabolic derangements; (b) rapid oral and/or intravenous rehydration for dehydration; (c) early, titrated IV fluids and vasoactive agents for shock, guided by serial vital signs and perfusion markers; (d) prompt antibiotics for concurrent bacterial infections including sepsis; and (e) structured post-recovery survivor care to address viral persistence and long-term sequelae. 6. Methodologic rigor: Recommendations were informed by multidisciplinary expert consultations, systematic evidence appraisal, and GRADE-based evidence-to-decision frameworks considering benefits, harms, equity, feasibility, resource use, and acceptability; specific effect sizes and confidence intervals are not reported in the available abstract.
Practice implications
Clinicians managing suspected or confirmed filovirus disease should immediately implement the five core supportive-care pillars outlined in these guidelines: prioritized point-of-care laboratory monitoring (glucose, electrolytes, perfusion markers), aggressive oral or IV rehydration, early vasopressor initiation guided by serial hemodynamic assessment, empiric broad-spectrum antibiotics when secondary bacterial sepsis is suspected, and structured post-discharge survivor follow-up given the risk of viral persistence in immune-privileged sites. For patients infected with Marburg, Bundibugyo, or Sudan virus — where no licensed antivirals or vaccines exist — optimized supportive care represents the only evidence-based survival intervention and should be initiated without delay, as it is also a prerequisite for enrollment in antiviral clinical trials. Health systems in endemic regions and outbreak-response teams should integrate these guidelines into national preparedness plans, ensuring adequate laboratory infrastructure, vasoactive drug supply chains, and trained personnel to deliver individualized, patient-centered care in accordance with the WHO's new harmonized framework.